| Description | Telratolimod (MEDI9197) is a toll-like receptors 7/8 agonist. It has an antitumor activity. |
| In vivo | Telratolimod (50 μg) suppresses the tumor volume and more effectively blocks tumor growth in combination with CpG ODN in BALB/c mice bearing CT26 colon carcinoma cells. Telratolimod (100 μg) plus 200 μg of CpG ODN slows tumor growth and prolongs the survival of mice bearing large tumors [1]. |
| Synonyms | MEDI9197, 3M-052 |
| molecular weight | 593.89 |
| Molecular formula | C36H59N5O2 |
| CAS | 1359993-59-1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 60 mg/mL (101.02 mM), Sonication is recommended. |
| References | 1. Zhao BG, et al. Combination therapy targeting toll like receptors 7, 8 and 9 eliminates large established tumors. J Immunother Cancer. 2014 May 13;2:12. |